FDA expands Xenoview indication down to 6 years for MRI lung ventilation evaluation

FDA Issues Expanded Pediatric Approval of MRI Contrast Agent for Lung Ventilation Assessment

Previously approved for MRI lung ventilation evaluation in adults and children 12 and older, the hyperpolarized contrast agent Xenoview can now be utilized for pediatric patients six years and older.

FDA expands Xenoview indication down to 6 years for MRI lung ventilation evaluation

The hyperpolarized contrast agent for oral inhalation can now be used in patients 6 years and older, lowering the approved indication from 12 years of age.